Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioCardia is a clinical-stage regenerative medicine company focused on developing cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead platform, CardiAMP, is an autologous cell therapy system that uses a patient's own bone marrow cells to treat ischemic heart failure and chronic myocardial ischemia. BioCardia's approach integrates a proprietary molecular diagnostic for patient selection, a point-of-care cell processing platform, and the Helix transendocardial delivery system. The company is also developing CardiALLO, an allogeneic cell therapy, and partners with other firms to provide its specialized delivery technologies for various biologic therapies.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on CardiAMP.